

Charity registration number: 1198095
Company registration number: CEO28473

AMMF - The Cholangiocarcinoma Charity

(A Charitable Incorporated Organisation)

Annual Report and Financial Statements

for the Year Ended 31 January 2025

Edmund Carr LLP
Chartered Accountants & Statutory Auditor
146 New London Road
Chelmsford
Essex
CM2 0AW

AMMF - The Cholangiocarcinoma Charity

Contents

Reference and Administrative Details	1
Trustees' Report	2 to 13
Statement of Trustees' Responsibilities	14
Independent Auditor's Report	15 to 19
Statement of Financial Activities	20
Balance Sheet	21
Statement of Cash Flows	22
Notes to the Financial Statements	23 to 33

AMMF - The Cholangiocarcinoma Charity

Reference and Administrative Details

Chairman	Mr Noel Corrigan
Trustees	Mrs Gillian Corrigan Mr Harold Corrigan Mr Tom Morement
Senior Management / Leadership Team	Mrs Helen Morement, CEO
Registered Office	Enterprise House Bassingbourn Road Stansted Essex CM24 1QW The charity is incorporated in England and Wales.
Charity Registration Number	1198095
Company Registration Number	CEO28473
Auditor	Edmund Carr LLP Chartered Accountants & Statutory Auditor 146 New London Road Chelmsford Essex CM2 0AW

**AMMF – THE CHOLANGIOCARCINOMA CHARITY
(REGISTERED NO: 1198095)**

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 JANUARY 2025**

NOTE FROM THE TRUSTEES:

AMMF – The Cholangiocarcinoma Charity was registered with the Charity Commission as a Charitable Incorporated Organisation (CIO) during the year 2022. The CIO registered number with the Charity Commission is 1198095.

The charity was originally registered in 2002 under the name, The Alan Morement Memorial Fund (working title, AMMF) and was an unincorporated charity with the registration number 1091915.

However, because of the continuing growth of the charity, AMMF's trustees decided that it should transition as a legal entity from unincorporated registered charity status to that of a Charitable Incorporated Organisation (CIO). This involved lengthy work with the Charity Commission, and the new CIO status was approved on 01 June, 2022. At that point the work and all assets of the original charity passed to the new CIO charity.

The original charity and its registered number 1091915 will always remain in existence, with all records submitted to the Charity Commission still available on the Commission's website, but this entity will now remain in the background.

The new CIO is officially known as: AMMF – The Cholangiocarcinoma Charity, with the registered number: 1198095.

AMMF 's aims and objectives remain unchanged and the charity's work has continued seamlessly and without interruption since the inception of the CIO on 01 June 2022.

AMMF- The Cholangiocarcinoma Charity

Trustees' Report

The trustees present their report with the financial statements of the charity for the year ended 31 January 2025. The trustees have adopted the provisions of Accounting and Reporting by Charities:

Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

AMMF's MISSION

A world improved for the cholangiocarcinoma patient by the sharing of knowledge across the healthcare and research communities and with the family of affected people across the globe.

AMMF's VISION

A world where people can live their lives free of cholangiocarcinoma (CCA) as a life-threatening disease.

AMMF – the Cholangiocarcinoma Charity is the only charity in the UK solely dedicated to cholangiocarcinoma (bile duct cancer). AMMF works nationally throughout the UK, as well as in Europe, and collaborates globally.

AMMF is wholly committed nationally and internationally to tackling the devastating primary liver cancer, cholangiocarcinoma (CCA) on all fronts and, ultimately, to help find a cure, through:

- **Support** - Providing information to individuals or groups to support a patient or loved one along their journey
- **Empowerment** – Empowering patients and their loved ones to advocate for themselves, seek better care, new treatment options and second opinions
- **Access** – Advocating for patients to ensure they have access to the latest treatment options and a minimum standard of care appropriate to them
- **Awareness** – Raising awareness of cholangiocarcinoma to support earlier diagnosis, fair and equal access to treatments, including new treatment approaches
- **Research** – Encouraging and supporting continued research into causes, diagnostics, and new treatment options for those with cholangiocarcinoma
- **Policy** – Working towards ensuring health care policies reflect the needs of those with cholangiocarcinoma

AMMF- The Cholangiocarcinoma Charity

Trustees' Report

Cholangiocarcinoma is under-represented and under-funded across all areas, including policy, services, and research. It is a poorly understood and under researched disease which is increasing in incidence not only in the UK but throughout the world. Lack of awareness and the difficulties of achieving clear and accurate diagnosis, mean that most are at an advanced stage and inoperable at time of their diagnosis.

Whilst surgery remains the only potentially curative treatment, there is now chemotherapy, targeted therapies and immunotherapy, and a growing number of clinical trials, in particular those investigating further targeted therapies and immunotherapies. However, a diagnosis of inoperable cholangiocarcinoma remains invariably fatal, and this is a situation that has not changed in decades. AMMF is committed to working to change this scenario, nationally and internationally.

Resolute in bringing about improvement for the cholangiocarcinoma patient, AMMF continues to work closely with patients and their carers, clinicians, healthcare professionals, researchers, and policy makers, as well as actively collaborating globally.

During the year 2024, the charity continued its advocacy work, especially in helping those with cholangiocarcinoma to navigate their way to continue essential treatments wherever possible.

Raising Awareness

The Rethink Liver Cancer Campaign

The aim of AMMF's 'Rethink Liver Cancer' campaign is to broaden the focus of liver cancer from being exclusively hepatocellular carcinoma (HCC) to highlight that cholangiocarcinoma (CCA) is also a primary liver cancer, and to raise awareness and influence health policy for better recognition, earlier diagnosis, and equitable treatment access.

'Soft launched' in October 2023 (Liver Cancer Awareness Month), The Rethink Liver Cancer Campaign, was formally launched on 20 February 2024 with a White Paper¹ based on the outcomes and the publications from AMMF's CCA data work, at an afternoon tea reception in The Terrace Pavillion at the House of Commons, Westminster.

AMMF's Westminster Reception - February 2024

Elliot Colburn MP, Chair of the All Party Parliamentary Group on Cancer, hosted the event and met and spoke with many of the guests. Noel Corrigan, Chair of AMMF's Trustees, introduced the formal part of the afternoon, Elliot Colburn gave an introductory talk, and AMMF's new video² showcasing the findings of the CCA data project was premiered. Helen Morement, AMMF's CEO, and Professor Shahid Khan of Imperial College London, then spoke about what led to the CCA data project, the results and the asks we now have for those who can change policy and improve the situation for all those with CCA.

AMMF- The Cholangiocarcinoma Charity Trustees' Report

Amongst the attendees were a number of health care professionals with an interest in CCA, MPs and government health officials, NHS policy makers, patients and carers, and members of the press.

AMMF's Westminster reception resulted in press coverage of the event and the White Paper in some 140 different media outlets, nationally and internationally.

¹ <https://ammf.org.uk/rethink-liver-cancer-white-paper/>

² <https://www.youtube.com/watch?v=8C2nlz3-bc8&t=25s>

AMMF's Hybrid European Cholangiocarcinoma Conference - May 2024

AMMF's European Cholangiocarcinoma Conference 2024 was a three-day hybrid event showcasing groundbreaking research, innovative treatments, and the collaborative spirit of the cholangiocarcinoma (CCA) community.

The charity was delighted to welcome two internationally renowned specialists at the forefront of the CCA world, Professor Shahid Khan and Professor Chiara Braconi, as co-chairs of the 2024 conference. They expertly hosted a faculty of 45 international speakers and managed some challenging Q & A sessions, all exploring the conference theme – Accelerating Progress.

As in previous years, the conference brought together a diverse audience, including healthcare professionals (HCPs), researchers, medical students, patient organisations, patients, carers and patient advocates. This mix provided a unique platform for exchanging knowledge and perspectives, enhancing the understanding and management of CCA.

Impactful personal perspectives were shared by four CCA patients. Their powerful individual stories highlighted real-world challenges including the crucial need for specialist knowledge, early diagnosis, and comprehensive support systems.

AMMF's conference was endorsed by the [British Society for the Study of the Liver](#), and was a CPD accredited event, worth 22.5 hours CPD (Continuing Professional Development).

The full programme and all conference presentations from the three days were recorded and remain available to view via AMMF's website. See: <https://ammf.org.uk/ammf-conference-2024/>

AMMF Clinical Nurse Specialist Advisory Board – May 2024

On 08 May 2024, during AMMF's CCA conference, a workshop for Clinical Nurse Specialists (CNS) was held. Following this, at the nurses' request, an AMMF CNS Advisory Board has been set up. CNS Advisory Board Terms of Reference were prepared, circulated and approved, and a virtual meeting of the board will be scheduled for early in 2025.

AMMF- The Cholangiocarcinoma Charity Trustees' Report

Faces of Cholangiocarcinoma – December 2024

The 'Faces of Cholangiocarcinoma' initiative was part of the next stage of the Rethink Liver Cancer campaign, which it is planned will run throughout 2025. To promote the ask for a 'Fairer Deal, Faster' for all those with cholangiocarcinoma, a photo shoot was arranged with the celebrity photographer, Rankin (Rankin waived his fee for the day, although the charity had to pay for the studio and ancillary personnel). Eight people with cholangiocarcinoma were photographed, including the designer Dame Zandra Rhodes, Katie Nichol (author and royal commentator), Charlie Shrager (model), and others well known to AMMF - Ilona Smith, Andrea Sheardown, Andy Clay, Judith Neptial, Benjamin Carey.

As part of this venture, a 'behind the scenes' video was created, which will be launched at the start of February 2025, Cholangiocarcinoma Awareness Month:

<https://www.youtube.com/watch?v=vDZ7mrkl86U>

And a new campaign video, "Rethink Liver Cancer – for a Fairer Deal Faster" for 2025 has been created, using interviews and film captured during the day at Rankin's studio:

<https://www.youtube.com/watch?v=9loCFcubudI>

Global Cholangiocarcinoma Alliance

The Global Cholangiocarcinoma Alliance (GCA) was established at AMMF's international workshop held in London in 2018. The aim of the Alliance is to provide a united voice through international collaboration, raise the global awareness of CCA, and to improve the education of both healthcare professionals and patients.

Since the GCA's inception in 2018, AMMF has acted as the not-for-profit partner in this venture, and AMMF's CEO Helen Morement is a co-chair on the international steering committee.

During 2024 the role of secretariat of the GCA, and the organisation of the annual World Cholangiocarcinoma Day in February, Cholangiocarcinoma Awareness Month, passed from the healthcare communications agency AXON to Colab Health who will now also manage the bespoke website and social media accounts.

Public Benefit

In forming the charity's objectives and planning the activities, the trustees have considered the Charity Commission's guidance in respect of public benefit.

ACHIEVEMENT AND PERFORMANCE

AMMF's Research Awards

AMMF- The Cholangiocarcinoma Charity Trustees' Report

AMMF remains committed to supporting research into cholangiocarcinoma. In 2024, based on the advice of AMMF's Scientific Advisory Board awards were offered and accepted by the following to support their research into cholangiocarcinoma:

University of Birmingham (Mr Kayani Kayani) – AMMF Ref: 2024/224

“Stable functional induced tregs: A novel means of immunosuppression for patients transplanted for cholangiocarcinoma in the era of transplant oncology”

Award: £99,557.81 (to be given in one instalment)

University College London Hospital (Dr Uma Mukherjee) – AMMF Ref: 2024/225

“Identifying and predicting resistance mutations in intrahepatic cholangiocarcinoma (iCCA)”

Award: £17,331.73 (to be given in two instalments)

Imperial College London (Prof Shahid Khan) – AMMF Ref: 2024/226

“Multiplexed detection of cell-free DNA, microRNA, and protein biomarkers to diagnose Cholangiocarcinoma and Hepatocellular Carcinoma using a novel nanopore-based sensing technology”

Award: £45,000.00 (to be given in two instalments)

During 2024 the following payments were made re existing awards:

University of Nottingham - AMMF Ref: 2022/214

An award totalling £24,250.00 was agreed to fund consumables in the work of Professor Kevin Gaston, Professor Sheela Jayaraman and Dr Isioma Egbuniwe on, “Ultra high-resolution mapping of spatial patterns of gene and protein expression in cholangiocarcinoma and the cholangiocarcinoma tumour microenvironment”.

The following payments (totalling £24,010.05) were made in respect of invoices received, for consumables used:

£5,472.00 was paid on 07.03.2024

£2,226.67 was paid on 29.05.2024

£2,226.67 was paid on 14.06.2024

£14,084.71 was paid on 23.12.2024

University of Glasgow – AMMF ref: 2023/218

£49,732.00 was paid on 18.03.24 representing the first instalment of the award of £99,464.00 agreed to fund the work of Professor Chiara Braconi and Dr Jen Morton in, “Identifying therapeutic opportunities for Biliary Cancers by investigating the role of Monocytes in drug response”.

AMMF- The Cholangiocarcinoma Charity Trustees' Report

Imperial College London – AMMF Ref: 2024/226

£22,500.00 was paid on 23.12.24 representing the first instalment of the award of £24,000.00 agreed to fund the work of Professor Shahid Khan in, “Multiplexed detection of cell-free DNA, microRNA, and protein biomarkers to diagnose Cholangiocarcinoma and Hepatocellular Carcinoma using a novel nanopore-based sensing technology”.

AMMF's External Activities

The charity is recognized widely, nationally and internationally, amongst both the general public and within medical circles, for its work in the field of cholangiocarcinoma, and is frequently invited to become part of study groups and advisory boards, for example, the working group for Liver Transplantation for Cholangiocarcinoma, and the executive committee of Cholangiocarcinoma-UK.

AMMF is also a member of the European Network for the Study of Cholangiocarcinoma (ENS-CCA), an association of research groups from across Europe and beyond, actively working on basic, translational, and clinical research into cholangiocarcinoma, and AMMF's CEO is chair of the ENS-CCA Patient Advocacy Committee.

AMMF continues to be an active member of Cancer52, the alliance of rare and less common cancer organisations in the UK. AMMF's CEO, Helen Morement was appointed a board director/trustee of Cancer52 in 2014, and has continued in that role since then. She also acted as interim co-chair during 2023 and part of 2024 (with fellow Cancer52 board member, Rebecca Porta, CEO of The Urology Foundation) until the new Chair of Trustees was appointed. Through membership of Cancer52, AMMF is enabled to have a presence and a voice within every national cancer initiative and AMMF's trustees see this as providing an important opportunity to work more closely with this influential organisation, and in identifying priority challenges and opportunities for all those in the rare and less common cancers community.

BSG (British Society for Gastroenterology) Guidelines for the Diagnosis and Management of Cholangiocarcinoma

Led by Professor Shahid Khan, Imperial College London, and originally published in 2023, the guidelines which had been prepared by a multidisciplinary writing committee of UK experts from various specialties involved in the diagnosis and management of CCA, including AMMF's CEO, were updated during 2024 to include information on molecular profiling, targeted therapies, and the follow-up protocol after surgical resection for cholangiocarcinoma.

AMMF's CEO, Helen Morement, also had discussions with David Fitzgerald, Director – Policy and Strategy, NHS Cancer Programme, NHS England, who agreed that the guidelines, along with a data analysis of the various CCA therapies given, cancer alliance by cancer alliance (extracted from AMMF's published data work), should be circulated to all cancer alliances in England. This was done in October 2024.

AMMF- The Cholangiocarcinoma Charity Trustees' Report

For more information and the BSG guidelines, see: <https://ammf.org.uk/guidelines-for-the-diagnosis-and-management-of-cholangiocarcinoma/>

HPB Pathway to Diagnosis

During the year, AMMF's CEO worked with Peter Hawkins, Programme Manager for Faster Diagnosis, NHS Cancer Programme, NHS England, on the HPB (Hepatobiliary) Cancers Diagnostic Pathways document. This document is to be used by all cancer alliances, their respective NHS trusts and other stakeholders. See: <https://www.england.nhs.uk/publication/implementing-a-timed-hpb-cancer-diagnostic-pathway-pancreatic-liver-bile-duct-and-gall-bladder/>

New therapy appraisals:

NICE (National Institute for Care and Excellence) and SMC (Scottish Medicines Consortium)

During 2024, AMMF was invited to submit written and oral statements in support of new therapy appraisals by NICE and the SMC. Following submissions and full appraisals, the following new therapies for cholangiocarcinoma were approved during 2024:

By NICE:

- Futibatinib (Lytgobi): for those with a previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement.

By the SMC:

- Ivosidenib (Tibsovo): a 2nd line treatment for those with an IDH1 mutation.

External events

As the charity continues to expand its work throughout the UK and into Europe, during the year AMMF's CEO received a number of invitations to speak about cholangiocarcinoma and the work of the charity at national and international conferences during the year and presented at the following:

- 02 February - CCA-UK (Cholangiocarcinoma-UK): Annual Meeting, London.
- 08 February - ILCM (International Liver Cancer Movement) CCA Webinar (virtual).
- 15 February - APiC (Italian CCA Patients Association) Annual meeting (virtual).
- 26 -27 April - ILCA (International Liver Cancer Association) Congress, Madrid, Spain.

AMMF- The Cholangiocarcinoma Charity Trustees' Report

- 01-02 July - ENS-CCA (European Network for the Study of Cholangiocarcinoma) Conference, Krakow, Poland.
- 19 July - NHS England – Circulating DNA (CtDNA) and Genomics Conference, London.
- 13 – 17 September, ESMO (European Society of Medical Oncology) Annual Congress and ATUVIBI (Spanish CCA advocacy group) event, Barcelona, Spain.
- 30 September - University of Glasgow & University of Edinburgh, NHS Scotland – Scottish Perspective on Biliary Cancers – Dunblane, Scotland.

Other external events:

- 01 – 06 June – ASCO 2024. AMMF's CEO Helen Morement and trustee Gillian Corrigan attended this internationally renowned annual oncology event in Chicago, USA. This provided an opportunity for meeting with and fostering new pharmaceutical industry relationships, and with international CCA specialists and other patient advocacy groups. They also attended the ABC-07 trial outcome presentation and, as the CEO was a member of the trial management group headed by Professor Maria Hawkins, who is a member of AMMF's Clinical and Medical Advisory Board, it was considered important for AMMF to have a presence at this event.
- 10 October: Nottingham Nurses' Event - two members of AMMF's team (Natasha Pite and Julie Cross) attended the event to showcase the work of the charity and the resources the charity has for both nurses and patients.

AMMF's CEO Awarded an Honorary Doctorate

On 17 July 2024, Helen Morement, the founder and Chief Executive of AMMF – The Cholangiocarcinoma Charity was awarded the honorary degree of Doctor of Science *honoris causa* in a graduation ceremony at the University of Nottingham in recognition of her service to medicine and science over more than two decades.

Helen was nominated for this prestigious degree by Professor Kevin Gaston, Professor of Cancer Sciences, Faculty of Medicine and Health Sciences at the University of Nottingham. The award recognises her outstanding contribution through the work of AMMF, in the field of cholangiocarcinoma.

AMMF- The Cholangiocarcinoma Charity

Trustees' Report

Professor David Bates, Professor of Oncology and Director of the University of Nottingham's Centre for Cancer Sciences, delivered an Oration in which he outlined Helen's work explaining that, as a consequence of this work, development of and access to clinical trials, surgery, information and drug therapies have improved, and that she continues to advocate for a more widespread approach for fair and equitable treatment.

Providing information for those who need it

AMMF's CEO attended the virtual NHS cancer charity briefing meetings throughout 2024. These regular meetings have proved helpful and informative, providing details of new developments in NHS processes and policies in a timely manner. AMMF's Medical and Clinical Advisors are contacted on a regular basis for help and advice on how best to handle the more difficult patient queries the charity receives, and for up to date information on clinical trials.

AMMF's website continued to be updated regularly, and provides information on all aspects of cholangiocarcinoma, including treatments and specialists, the advances being made and, importantly, there is a comprehensive list of the clinical trials that are available and recruiting in the UK, which is proving a valuable resource to healthcare professionals and patients. www.ammf.org.uk

The charity uses a number of social media platforms – Facebook, X (formerly Twitter), Instagram, LinkedIn. These are each kept up to date with daily information of importance and relevance to supporters. The number of followers on each continues to grow, with Facebook in particular now at over 6,300 followers.

AMMF's three private, member only, support groups on Facebook, Cholangiocarcinoma Support – UK and Europe: for Patients and Carers, for Patients Only, and for those bereaved, continue to grow, The groups provide an invaluable resource for patients and their loved ones and, moderated by three knowledgeable volunteers, each group is a safe and private space in which to share information, and to help and support each other.

The requirement from individual patients and family members for specific information regarding specialist consultants and treatments continues to increase. With the wider awareness of the charity, increasing incidence and growing recognition of cholangiocarcinoma, it is anticipated this area of work will continue to grow.

AMMF- The Cholangiocarcinoma Charity Trustees' Report

As we look to 2025 ...

The Rethink Liver Cancer Campaign and Westminster Reception 2025

The Rethink Liver Cancer campaign is ongoing and will continue into 2025, especially during February's Cholangiocarcinoma Awareness Month when we will be holding a further reception in Westminster, in the House of Commons Churchill Room. The event will be hosted by Mary Glendon, MP for Newcastle upon Tyne East & Wallsend. We hope those who took part in the Faces of Cholangiocarcinoma event in December 2024 will attend, to add strength to the charity's ask of those with the power to change policy for a 'fairer deal faster' for all those diagnosed with cholangiocarcinoma.

Centres of CCA Expertise

The outcomes of the CCA data project and the publication of the new BSG Guidelines for the Diagnosis and Management of CCA gave AMMF the ammunition to begin work towards building the case for Centres of CCA Expertise. During 2024, a working group of specialists in CCA has joined with AMMF in this work, and in planning a hospital audit to ascertain the numbers of those diagnosed with CCA and the treatments they actually receive.

AMMF's Hybrid European Cholangiocarcinoma Conference 2025

The 2025 conference will take place **07 – 09 May** with a global faculty and co-chairs, Dr Heinz-Josef Klumpen and Ms Rachel Guest, two internationally renowned specialists at the forefront of the CCA world.

And Finally

AMMF has grown steadily over the years and, with the continued help of loyal fundraisers and supporters, sponsor and advisors, we will continue our work and remain fully committed to working towards a far better future for all those diagnosed with cholangiocarcinoma.

At the heart of everything we do is the cholangiocarcinoma patient and their families, and each and every day all of us at AMMF strive towards that improved future for all those diagnosed with this most challenging of cancers. AMMF will continue its work until that goal is reached.

Financial review

Financial review and reserves policy

The charity has continued to strengthen its financial position during the year.

The charity ensures that sufficient reserves are retained in an appropriate form to fund its current obligations.

Where specific research projects have been secured, the trustees designate sufficient unrestricted reserves to cover the expected future grants payable over the term of the research project.

AMMF- The Cholangiocarcinoma Charity Trustees' Report

Note 15 to the financial statements details the movement on restricted and unrestricted funds during the accounting period. Of total funds, £1,112,245 is freely available because the balance has a restriction for other purposes. Restricted funds totalled £147,539 and total funds for the period were £1,259,784.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes an incorporated charity.

Approved by order of the board of trustees on^{25 November 2025} and signed on its behalf by:

.....*Noel Corrigan*..... Noel Corrigan – Chair of Trustees

AMMF - The Cholangiocarcinoma Charity

Statement of Trustees' Responsibilities

The trustees (who are also the directors of AMMF - The Cholangiocarcinoma Charity for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland". The report and accounts have been prepared in accordance with the provisions in the Companies Act 2006 relating to small companies.

Company law requires the trustees to prepare financial statements for each financial year. Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including its income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards, comprising FRS 102 have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records that can disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

AMMF - The Cholangiocarcinoma Charity

Independent Auditor's Report to the Members of AMMF - The Cholangiocarcinoma Charity

Opinion

We have audited the financial statements of AMMF - The Cholangiocarcinoma Charity (the 'charity') for the year ended 31 January 2025, which comprise the Statement of Financial Activities, Balance Sheet, Statement of Cash Flows, and Notes to the Financial Statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charity's affairs as at 31 January 2025 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Comparative period

The financial statements for the year ended 31 January 2024 were subject to an independent examination and not an audit. Accordingly, the comparative information presented does not include an auditor's opinion.

AMMF - The Cholangiocarcinoma Charity

Independent Auditor's Report to the Members of AMMF - The Cholangiocarcinoma Charity

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the charity's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

AMMF - The Cholangiocarcinoma Charity

Independent Auditor's Report to the Members of AMMF - The Cholangiocarcinoma Charity

Opinion on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees' Report (incorporating the Directors' Report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Directors' Report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 require us to report to you if, in our opinion:

- the information given in the financial statements is inconsistent in any material respect with the trustees' report; or
- the charitable company has not kept adequate accounting records; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the Statement of Trustees' Responsibilities (set out on page 14), the trustees (who are also the directors of the charity for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Auditor responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with regulations made under section 154 of that Act.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

AMMF - The Cholangiocarcinoma Charity

Independent Auditor's Report to the Members of AMMF - The Cholangiocarcinoma Charity

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The specific procedures for this engagement and the extent to which these are capable of detecting irregularities, including fraud is detailed below:

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows;

- The engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations.
- We identified the laws and regulations applicable to the charity through discussions with Trustees and other management, and from our knowledge and experience of the charity sector.
- We focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations for the charity, data protection, employment and health and safety legislation.
- We assessed the extent of compliance with the laws and regulations identified above through making enquiries of management.

We assessed the susceptibility of the charity's financial statements to material misstatement, including obtaining an understanding of how fraud might occur by;

- Making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud.
- Considering the internal controls in place to mitigate the risks of fraud and non-compliance with laws and regulations.

To address the risk of fraud through management bias and override of controls, we;

- Performed analytical procedures to identify any unusual or unexpected relationships
- Tested journal entries to identify unusual transactions
- Investigated the rationale behind significant or unusual transactions

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities is available on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Edmund Carr LLP

.....
Edmund Carr LLP
Statutory Auditor

146 New London Road
Chelmsford
Essex
CM2 0AW

AMMF - The Cholangiocarcinoma Charity

**Independent Auditor's Report to the Members of AMMF - The Cholangiocarcinoma
Charity**

Date: 26 November 2025

Edmund Carr LLP is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006.

AMMF - The Cholangiocarcinoma Charity

Statement of Financial Activities for the Year Ended 31 January 2025 (Including Income and Expenditure Account and Other Comprehensive Income)

					(As restated)
	Note	Unrestricted £	Restricted £	Total 2025 £	Total 2024 £
Income and Endowments from:					
Donations and legacies	2	756,689	262,781	1,019,470	927,831
Other trading activities	3	6,422	-	6,422	12,470
Investment income	4	19,929	-	19,929	11,854
Total income		783,040	262,781	1,045,821	952,155
Expenditure on:					
Raising funds		2,703	-	2,703	6,271
Charitable activities	5	516,091	302,638	818,729	876,359
Total expenditure		518,794	302,638	821,432	882,630
Net income/(expenditure)		264,246	(39,857)	224,389	69,525
Transfers between funds		(106,800)	106,800	-	-
Net movement in funds		157,446	66,943	224,389	69,525
Reconciliation of funds					
Total funds brought forward		954,799	80,596	1,035,395	965,870
Total funds carried forward	17	1,112,245	147,539	1,259,784	1,035,395

All of the charity's activities derive from continuing operations during the above two periods.

AMMF - The Cholangiocarcinoma Charity

(Registration number: CEO28473)

(Charity number: 1198095)

Balance Sheet as at 31 January 2025

	Note	2025 £	(As restated) 2024 £
Fixed assets			
Tangible assets	10	7,783	4,219
Current assets			
Stocks	11	9,839	6,635
Debtors	12	85,287	69,633
Cash at bank and in hand	13	1,394,776	1,142,072
		1,489,902	1,218,340
Creditors: Amounts falling due within one year	14	(237,901)	(187,164)
Net current assets		1,252,001	1,031,176
Net assets		1,259,784	1,035,395
Funds of the charity:			
Restricted income funds			
Restricted funds	17	147,539	80,596
Unrestricted income funds			
Unrestricted funds		1,112,245	954,799
Total funds	17	1,259,784	1,035,395

The financial statements on pages 20 to 33 were approved by the trustees, and authorised for issue on 25 November 2025 and signed on their behalf by:

Noel Corrigan

Mr Noel Corrigan
Chairman

AMMF - The Cholangiocarcinoma Charity

Statement of Cash Flows for the Year Ended 31 January 2025

	Note	2025 £	(As restated) 2024 £
Cash flows from operating activities			
Net movement in funds per SOFA		224,389	69,525
Adjustments			
Depreciation		3,432	2,551
Investment income	4	<u>(19,929)</u>	<u>(11,854)</u>
		207,892	60,222
Working capital adjustments			
(Increase)/decrease in stocks	11	(3,204)	751
Increase in debtors	12	(15,654)	(29,422)
Increase in creditors	14	25,737	127,776
Increase in deferred income		<u>25,000</u>	<u>-</u>
Net cash flows from operating activities		<u>239,771</u>	<u>159,327</u>
Cash flows from investing activities			
Interest receivable and similar income	4	19,929	11,854
Purchase of tangible fixed assets	10	<u>(6,996)</u>	<u>(155)</u>
Net cash flows from investing activities		<u>12,933</u>	<u>11,699</u>
Net increase in cash and cash equivalents		252,704	171,026
Cash and cash equivalents at 1 February		<u>1,142,072</u>	<u>971,046</u>
Cash and cash equivalents at 31 January		<u><u>1,394,776</u></u>	<u><u>1,142,072</u></u>

All of the cash flows are derived from continuing operations during the above two periods.

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2025

1 Accounting policies

Statement of compliance

The accounts (financial statements) have been prepared in accordance with the statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 16 July 2014 and the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Charities Act 2011 and UK Generally Accepted Practice as it applies from 1 January 2019.

The accounts (financial statements) have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair view'. This departure has involved following Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 16 July 2014 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

Basis of preparation

AMMF - The Cholangiocarcinoma Charity meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

Going concern

The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the charity.

Income and endowments

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of the income receivable can be measured reliably.

Donations and legacies

Donations are recognised when the charity has been notified in writing of both the amount and settlement date. In the event that a donation is subject to conditions that require a level of performance by the charity before the charity is entitled to the funds, the income is deferred and not recognised until either those conditions are fully met, or the fulfilment of those conditions is wholly within the control of the charity and it is probable that these conditions will be fulfilled in the reporting period.

Deferred income

Deferred income represents amounts received for future periods and is released to incoming resources in the period for which, it has been received. Such income is only deferred when:

- The donor specifies that the grant or donation must only be used in future accounting periods; or
- The donor has imposed conditions which must be met before the charity has unconditional entitlement.

Investment income

Dividends are recognised once the dividend has been declared and notification has been received of the dividend due.

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2025

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use. Other support costs are allocated based on the spread of staff costs.

Raising funds

These are costs incurred in attracting voluntary income, the management of investments and those incurred in trading activities that raise funds.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Governance costs

These include the costs attributable to the charity's compliance with constitutional and statutory requirements, including audit, strategic management and trustees meetings and reimbursed expenses.

Tangible fixed assets

Individual fixed assets costing £50.00 or more are initially recorded at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

Depreciation and amortisation

Depreciation is provided on tangible fixed assets so as to write off the cost or valuation, less any estimated residual value, over their expected useful economic life as follows:

Asset class	Depreciation method and rate
Computer equipment	33%

Stock

Stock is valued at the lower of cost and estimated selling price less costs to complete and sell, after due regard for obsolete and slow moving stocks. Cost is determined using the first-in, first-out (FIFO).

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the charity will not be able to collect all amounts due according to the original terms of the receivables.

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2025

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the charity does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees's discretion in furtherance of the objectives of the charity.

Restricted income funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose.

Financial instruments

Classification

Financial assets and financial liabilities are recognised when the charity becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charity after deducting all of its liabilities.

2 Income from donations and legacies

	Unrestricted funds £	Restricted funds £	Total funds £
Donations and legacies	756,689	262,781	1,019,470
Total for 2025	756,689	262,781	1,019,470
(As restated) Total for 2024	699,595	228,236	927,831

3 Income from other trading activities

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2025

	Unrestricted funds £	Restricted funds £	Total funds £
Trading income; Shop income	6,422	-	6,422
Total for 2025	6,422	-	6,422
Total for 2024	12,470	-	12,470

4 Investment income

	Unrestricted funds £	Total funds £
Interest receivable and similar income; Interest receivable on bank deposits	19,929	19,929
Total for 2025	19,929	19,929
Total for 2024	11,854	11,854

5 Expenditure on charitable activities

	Note	Unrestricted funds £	Restricted £	Total 2025 £	(As restated) Total 2024 £
European Conference costs		274,114	302,638	576,752	514,849
Grants to institutions		90,771	-	90,771	234,248
European Website costs		-	-	-	9,582
Depreciation, amortisation and other similar costs		3,432	-	3,432	2,551
Staff costs		133,689	-	133,689	109,782
Governance costs	6	14,085	-	14,085	5,347
		516,091	302,638	818,729	876,359

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2025

6 Analysis of governance and support costs

Governance costs

	Total 2025 £	Total 2024 £
Audit fees		
Audit of the financial statements	12,600	-
Independent examiner fees		
Accounts and independent examination	-	3,900
Payroll fees	284	878
Bookeeping fees	1,201	569
	<u>14,085</u>	<u>5,347</u>

7 Net incoming/outgoing resources

Net incoming resources for the year include:

	2025 £	2024 £
Audit fees	12,600	-
Depreciation of fixed assets	<u>3,432</u>	<u>2,551</u>

8 Trustees remuneration and expenses

During the year the charity made the following transactions with trustees:

Mr Harold Corrigan

£890 (2024: £616) of expenses were reimbursed to Mr Harold Corrigan during the year.

Mr Noel Corrigan

£767 (2024: £205) of expenses were reimbursed to Mr Noel Corrigan during the year.

Mr Tom Morement

£479 (2024: £Nil) of expenses were reimbursed to Mr Tom Morement during the year.

Mrs Gillian Corrigan

£2,648 (2024: £Nil) of expenses were reimbursed to Mrs Gillian Corrigan during the year.

9 Staff costs

The aggregate payroll costs were as follows:

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2025

	2025 £	2024 £
Staff costs during the year were:		
Wages and salaries	123,528	104,451
Social security costs	7,796	3,776
Pension costs	2,365	1,555
	<u>133,689</u>	<u>109,782</u>

The monthly average number of persons (including senior management / leadership team) employed by the charity during the year expressed by head count was as follows:

	2025 No	2024 No
Employees	<u>4</u>	<u>4</u>

No employee received emoluments of more than £60,000 during the year.

The total employee benefits of the key management personnel of the charity were £52,463.

10 Tangible fixed assets

	Computer equipment £	Total £
Cost		
At 1 February 2024	13,135	13,135
Additions	6,996	6,996
Disposals	<u>(3,682)</u>	<u>(3,682)</u>
At 31 January 2025	<u>16,449</u>	<u>16,449</u>
Depreciation		
At 1 February 2024	8,916	8,916
Charge for the year	3,432	3,432
Eliminated on disposals	<u>(3,682)</u>	<u>(3,682)</u>
At 31 January 2025	<u>8,666</u>	<u>8,666</u>
Net book value		
At 31 January 2025	<u>7,783</u>	<u>7,783</u>
At 31 January 2024	<u>4,219</u>	<u>4,219</u>

11 Stock

	2025 £	2024 £
Stocks	<u>9,839</u>	<u>6,635</u>

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2025

12 Debtors

	2025 £	(As restated) 2024 £
Trade debtors	18,800	-
Prepayments	54,279	46,231
Accrued income	12,208	23,402
	<u>85,287</u>	<u>69,633</u>

13 Cash and cash equivalents

	2025 £	2024 £
Cash on hand	202	25
Cash at bank	1,394,574	1,142,047
	<u>1,394,776</u>	<u>1,142,072</u>

14 Creditors: amounts falling due within one year

	2025 £	(As restated) 2024 £
Trade creditors	13,394	8,816
Accruals for grants	168,938	168,937
Other taxation and social security	3,945	1,077
Accruals	26,624	8,334
Deferred income	25,000	-
	<u>237,901</u>	<u>187,164</u>
		 2025
		£
Resources deferred in the period		<u>25,000</u>

Included within deferred income is £25,000 for sponsorship for the 2025 AMMF Conference.

15 Obligations under leases and hire purchase contracts

The total value of future minimum lease payments was as follows:

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2025

	2025 £	2024 £
Within one year	23,460	24,720
In two to five years	19,425	12,360
In over five years	4,770	-
	<u>47,655</u>	<u>37,080</u>

16 Contingent liabilities

At 31 January 2025 grants of £161,999 (2024: £101,645) had been awarded for which conditions for the recognition in the year had not been met.

17 Funds

Current year:

	Balance at 1 February 2024 £	Incoming resources £	Resources expended £	Transfers £	Balance at 31 January 2025 £
Unrestricted funds					
General Funds	954,799	783,040	(518,794)	(106,800)	1,112,245
Restricted					
Restricted Research Funds	21,120	11,818	-	-	32,938
European Website Project	23,606	5,000	(758)	-	27,848
European Conference 2024	-	140,963	(247,763)	106,800	-
External Projects	35,870	105,000	(54,117)	-	86,753
Total restricted	<u>80,596</u>	<u>262,781</u>	<u>(302,638)</u>	<u>106,800</u>	<u>147,539</u>
Total funds	<u>1,035,395</u>	<u>1,045,821</u>	<u>(821,432)</u>	<u>-</u>	<u>1,259,784</u>

Prior year:

	Balance at 1 February 2023 £	Incoming resources £	Resources expended £	Transfers £	(As restated) Balance at 31 January 2024 £
Unrestricted funds					
Unrestricted funds					
General Funds	876,124	723,919	(613,321)	(31,923)	954,799

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2025

	Balance at 1 February 2023 £	Incoming resources £	Resources expended £	Transfers £	(As restated) Balance at 31 January 2024 £
Restricted					
Restricted Research Funds	21,120	-	-	-	21,120
European Website Project	33,626	-	(10,020)	-	23,606
European Conference 2023	35,000	124,923	(191,846)	31,923	-
External Projects	-	103,313	(67,443)	-	35,870
Total restricted funds	89,746	228,236	(269,309)	31,923	80,596
Total funds	965,870	952,155	(882,630)	-	1,035,395

The specific purposes for which the funds are to be applied are as follows:

Restricted research funds represent donations where the donor has requested that their donation be used for research purposes only. These donations are held within restricted funds until utilised in part or in whole to fund a cholangiocarcinoma research project which the charity has committed to support.

Restricted funds for each of the major projects AMMF undertakes represent those donations or sponsorships where the donor has requested that their monies be used for that particular project only. Those funds are held as restricted funds until used in full or in part to complete the project for which they were given.

Restricted funds for the major, external projects AMMF undertakes represent sponsorships to support only those individual specific projects for which the funding has been given. The number of such projects varies from year to year.

The transfer of £106,800 represents restricted projects and events funded from unrestricted funds due to a shortfall in funding received.

18 Analysis of net assets between funds

	Unrestricted funds £	Restricted funds £	Total funds at 31 January 2025 £
Tangible fixed assets	7,783	-	7,783
Current assets	1,342,363	147,539	1,489,902
Current liabilities	(237,901)	-	(237,901)
Total net assets	1,112,245	147,539	1,259,784

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2025

	Unrestricted funds £	Restricted funds £	(As restated) Total funds at 31 January 2024 £
Tangible fixed assets	4,219	-	4,219
Current assets	1,137,744	80,596	1,218,340
Current liabilities	<u>(187,164)</u>	<u>-</u>	<u>(187,164)</u>
Total net assets	<u>954,799</u>	<u>80,596</u>	<u>1,035,395</u>

19 Related party transactions

There were no related party transactions in the year.

20 Prior period adjustment

Restatement of prior period balances has taken place, the adjustments were made due to under provided accrued income and accruals in the Year Ended 31 January 2024. As a result, in the comparative figures, donations and legacies income and accrued income have increased by £23,402 and charitable activity expenditure and accruals have increased by £4,434.

Also, the prior year contingent liability was also understated. The comparative in note 16 has been restated and increased by £14,325. This has no affect on the prior year's surplus or balance sheet.

AMMF - The Cholangiocarcinoma Charity

Notes to the Financial Statements for the Year Ended 31 January 2025

The following page does not form part of the statutory financial statements.

AMMF - The Cholangiocarcinoma Charity

Detailed Statement of Financial Activities for the Year Ended 31 January 2025

	Total 2025 £	Total 2024 £
Income and Endowments from:		
Donations and legacies	1,019,470	927,831
Other trading activities	6,422	12,470
Investment income	19,929	11,854
Total income	<u>1,045,821</u>	<u>952,155</u>
Expenditure on:		
Raising funds	(2,703)	(6,271)
Charitable activities	(818,729)	(876,359)
Total expenditure	<u>(821,432)</u>	<u>(882,630)</u>
Net income	<u>224,389</u>	<u>69,525</u>
Net movement in funds	224,389	69,525
Reconciliation of funds		
Total funds brought forward	<u>1,035,395</u>	<u>965,870</u>
Total funds carried forward	<u><u>1,259,784</u></u>	<u><u>1,035,395</u></u>